|
| Parameter | Value | Note |
|
| Maximum duration of each stage during disease development (latent, prodromal, and final), days | 4; 3; 4 | [30–32] |
| Day when disease passes from one stage to the other (see (1)) | 3; 2; 2 | [32, 33] |
| Mean number of contacts per one infected person | 5 | See |
| Duration of establishing postvaccination immunity, days | 1 | See (3) |
| Rate of infectious activity in final stage, % | 20 | See (4) |
| Rate of infectious activity of immune to nonimmune patients, % | 50 | [11] |
| Rate of infectious activity of cases with mild to severe forms, % | 10 | See (5) |
| Rate of severe forms among nonimmune patients, % | 40 | [34] |
| Rate of severe forms among immune patients, % | 20 | [35] |
| Rate of sensitivity to infection of immune patients relative to nonimmune ones, % | 20 | [25, 26] |
| Rate of infected contacts per day, % | 4 | See (6) |
| Mortality rate of nonimmune patients in prodromal stage, % | 0.1 | See (7) |
| Mortality rate of immune patients in prodromal stage, % | 0.03 | See (7) |
| Mortality rate of nonimmune patients with severe form in final stage, % | 0.2 | See (7) |
| Mortality rate of immune patients with severe form in final stage, % | 0.05 | See (7) |
| Mortality rate of patients with mild form in final stage, % | 0.01 | See (7) |
| Decrease in mortality rate of treated cases, % | 30 | [12] |
| Duration of contacts observation, days | 4 | [30–32] |
|
